Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Adaptimmune Ther ADR (ADAP)
Adaptimmune Ther ADR (ADAP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 447,396
  • Shares Outstanding, K 994,213
  • Annual Sales, $ 27,150 K
  • Annual Income, $ -165,460 K
  • 60-Month Beta 2.07
  • Price/Sales 17.40
  • Price/Cash Flow N/A
  • Price/Book 5.25
Trade ADAP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.58
  • Most Recent Earnings -0.20 on 11/08/23
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 79.92%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.16
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4200 +18.60%
on 11/28/23
0.6000 -16.98%
on 11/08/23
-0.0519 (-9.44%)
since 10/27/23
3-Month
0.4200 +18.60%
on 11/28/23
0.8500 -41.40%
on 09/14/23
-0.3019 (-37.74%)
since 08/29/23
52-Week
0.4200 +18.60%
on 11/28/23
2.3800 -79.07%
on 11/30/22
-1.6119 (-76.39%)
since 11/28/22

Most Recent Stories

More News
Adaptimmune Receives Transfer of IND for Lete-cel Program

Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma franchise...

ADAP : 0.4981 (+10.69%)
Adaptimmune Reports Third Quarter Financial Results and Business Update

Afami-cel: overall survival for people with synovial sarcoma who received afami-cel is superior to historic controls (CTOS 2023); BLA submission on track to complete in Q4 this yearSURPASS Phase 1 trial:...

ADAP : 0.4981 (+10.69%)
Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

Candidate is 10x more sensitive to target peptide than competitor candidatesEntry into the clinic in 2024Selection of approaches from next-gen toolbox in developmentPhiladelphia, Pennsylvania and Oxford,...

ADAP : 0.4981 (+10.69%)
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of response of ~12 months (CTOS 2022)Median overall survival (mOS) was ~17 months...

ADAP : 0.4981 (+10.69%)
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had clinical responses with lete-cel, by independent review[2]; primary efficacy endpoint requires...

ADAP : 0.4981 (+10.69%)
Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will report financial...

ADAP : 0.4981 (+10.69%)
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across a broad range of solid tumors 50% response rate in 26 patients...

ADAP : 0.4981 (+10.69%)
Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces that...

ADAP : 0.4981 (+10.69%)
Adaptimmune Reports Second Quarter Financial Results and Business Update

Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell potency assay - submission now targeted for Q4 2023Transition...

ADAP : 0.4981 (+10.69%)
Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results...

ADAP : 0.4981 (+10.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 0.5927
2nd Resistance Point 0.5506
1st Resistance Point 0.5243
Last Price 0.4981
1st Support Level 0.4559
2nd Support Level 0.4138
3rd Support Level 0.3875

See More

52-Week High 2.3800
Fibonacci 61.8% 1.6313
Fibonacci 50% 1.4000
Fibonacci 38.2% 1.1687
Last Price 0.4981
52-Week Low 0.4200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar